Barclays
ABUS icon

Barclays’s Arbutus Biopharma ABUS Stock Holding History

Barclays’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-75,000
Closed -$188K – 5039
2023
Q4 		$188K Buy
+75,000
New +$147K ﹤0.01% 4445
2018
Q3 		– Sell
-75,000
Closed -$548K – 7080
2018
Q2 		$548K Hold
75,000
– – ﹤0.01% 3869
2018
Q1 		$375K Buy
+75,000
New +$397K ﹤0.01% 4243

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Barclays's ABUS Position: Q2 2026 in Review

Barclays reduced its Arbutus Biopharma (ABUS) stake by 2.5% in Q2 2026, selling an estimated $475K and leaving 4,207,914 shares worth $20.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1127.

Barclays first reported a position in ABUS in Q2 2013 and has held it in 41 quarters since. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Barclays held 4,207,914 shares of Arbutus Biopharma worth $20.2M as of Q2 2026.
  • Barclays sold 108,181 Arbutus Biopharma shares in Q2 2026, an estimated $475K.
  • Arbutus Biopharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1127 holding.
  • Barclays first reported a position in Arbutus Biopharma in Q2 2013 and has held it in 41 quarters since.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.